Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide

Hematol Oncol Stem Cell Ther. 2019 Sep;12(3):171-173. doi: 10.1016/j.hemonc.2018.11.002. Epub 2018 Dec 9.

Authors

Ghulam Rehman Mohyuddin¹, John Roller², Leyla Shune², Tara Lin², Ajoy Dias², Siddhartha Ganguly², Sunil Abhyankar², Joseph McGuirk², Anurag Singh²

Affiliations

¹ Division of Hematologic Malignancies and Cellular, Therapeutics (HMCT), University of Kansas Medical Center, Kansas City, MO, USA. Electronic address: gmohy-ud-din@kumc.edu.
² Division of Hematologic Malignancies and Cellular, Therapeutics (HMCT), University of Kansas Medical Center, Kansas City, MO, USA.

PMID: 30543769
DOI: 10.1016/j.hemonc.2018.11.002

No abstract available

Publication types

Letter

MeSH terms

Cyclophosphamide / adverse effects*
Cyclophosphamide / therapeutic use
Epstein-Barr Virus Infections / etiology*
Female
Graft vs Host Disease / prevention & control
Hematopoietic Stem Cell Transplantation / adverse effects*
Hematopoietic Stem Cell Transplantation / methods
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Lymphoproliferative Disorders / etiology*
Male
Middle Aged
Viremia / etiology*

Substances

Immunosuppressive Agents
Cyclophosphamide